Using bumetanide to treat Alzheimer's disease
Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.
PHASE2 · Stanford University · NCT06052163
This study is testing if the diuretic bumetanide can help people with Alzheimer's disease feel better and improve their brain function compared to a placebo.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 50 Years to 85 Years |
| Sex | All |
| Sponsor | Stanford University (other) |
| Locations | 1 site (Stanford, California) |
| Trial ID | NCT06052163 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of bumetanide, a diuretic, on patients with biologically confirmed Alzheimer's disease. The research aims to evaluate the safety and tolerability of bumetanide, as well as its clinical and biomarker effects in individuals with mild cognitive impairment or mild dementia. The study builds on previous findings that suggest bumetanide may influence Alzheimer's disease pathology by altering gene expression related to the APOE genotype. Participants will receive either bumetanide or a placebo while their health and cognitive function are monitored.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 65 and older with mild cognitive impairment or mild dementia due to Alzheimer's disease.
Not a fit: Patients with significant liver or kidney issues, or those on certain contraindicated medications, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option for patients with Alzheimer's disease, potentially improving cognitive function and quality of life.
How similar studies have performed: Previous studies have shown promising results with bumetanide in Alzheimer's models, suggesting potential for success in this clinical application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Mild cognitive impairment or mild dementia due to Alzheimer's disease. * Alzheimer's disease medications are planned to remain stable throughout. * Willingness and ability to complete all aspects of the study including assessments, neuropsychological testing, and MRI. Exclusion Criteria: * Clinically significant abnormalities in screening laboratory tests * Chronic liver disease * Renal insufficiency * Poorly managed hypertension * Participants taking the following concomitant medications, based on the current Prescribing Information for bumetanide: lithium, drugs with ototoxic potential, drugs with nephrotoxic potential, probenecid, and indomethacin.
Where this trial is running
Stanford, California
- Stanford University — Stanford, California, United States (RECRUITING)
Study contacts
- Principal investigator: Kyan Younes, MD — Stanford University
- Study coordinator: Mina L Kim
- Email: minakim@stanford.edu
- Phone: (650) 387-1559
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Alzheimer Disease